Alkermes Reports $66.5 Million Net Loss Amid Increased Operating Expenses and Avadel Acquisition

Alkermes plc reported a net loss of $66.5 million, or $0.40 per ordinary share, for the three months ended March 31, 2026, a significant decline from a net income of $22.5 million, or $0.14 per share, during the same period in 2025. This change reflects an increase in total operating expenses by $148.5 million, primarily driven by costs associated with the recent acquisition of Avadel Pharmaceuticals, which included higher costs of goods sold, research and development (R&D) expenses, and selling, general, and administrative expenses. Total revenues for the quarter increased to $392.9 million from $306.5 million, largely due to a rise in product sales, net, which reached $338.1 million compared to $244.5 million in the prior year.

The company's financial performance was notably impacted by the Avadel Acquisition completed on February 12, 2026, which added LUMRYZ to its portfolio. The acquisition involved a cash payment of $21.00 per share for Avadel's ordinary shares and a contingent value right (CVR) that could yield an additional $1.50 per share upon achieving specific milestones. The acquisition resulted in a substantial increase in goodwill, which rose to $596.0 million from $83.0 million at the end of 2025. The total preliminary purchase consideration for the acquisition was approximately $2.3 billion, which included a contingent consideration liability of $107.7 million.

Operationally, Alkermes saw a significant increase in product sales, with LUMRYZ contributing $39.5 million in its first quarter of sales. Other key products, including VIVITROL, ARISTADA, and LYBALVI, also experienced growth, with sales increases of 11.4%, 20.3%, and 22.4%, respectively. The company reported a total of $336.7 million in inventory as of March 31, 2026, up from $196.6 million at the end of 2025, reflecting the inventory step-up from the Avadel acquisition. The total employee headcount increased by 15% due to the integration of Avadel's commercial organization.

Looking ahead, Alkermes anticipates that its existing cash, cash equivalents, and investments will be sufficient to meet its working capital and other cash requirements for at least the next twelve months. The company is focused on advancing its R&D pipeline, particularly in the field of neuroscience, with ongoing clinical trials for products like alixorexton, which has received Breakthrough Therapy designation from the FDA. Alkermes remains committed to its strategic goals while navigating the complexities introduced by the recent acquisition and the associated financial implications.